Safety of biosimilar filgrastim in patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study.

e20711 Background: Febrile neutropenia (FN) is a major risk factor for infection-related morbidity/mortality as well as a dose-limiting toxicity in patients (pts) undergoing chemotherapy (CT). Bios...